uniQure N.V.
About uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2017
- $13.1M
- Net income
- -$199.0M
- Total assets
- $824.9M
- Market cap
- $1.7B
- Gross margin
- 89.5%
- Operating margin
- -1151.4%
- Net margin
- -1236.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $16.1M
- Cost of revenue
- $1.7M
- Gross profit
- $14.4M
- Operating expenses
- $199.8M
- Operating income
- -$185.3M
- Income tax
- $5.6M
- Net income
- -$199.0M
- EPS (basic)
- $-3.46
- EPS (diluted)
- $-3.46
Balance sheet
- Total assets
- $824.9M
- Current assets
- $656.0M
- Total liabilities
- $626.0M
- Current liabilities
- $62.9M
- Shareholders’ equity
- $198.9M
Cash flow
- Operating cash flow
- -$178.0M
- Investing cash flow
- -$321.6M
- Financing cash flow
- $415.4M
- Net cash flow
- -$78.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.7B
- EPS (diluted)
- $-3.46
- Shares outstanding
- 61.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 5, 2014
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $199.0M in FY2017.
- Revenue declined 57% from FY2020 to FY2025.
- Gross margin of 89.5%, net margin -1236.0%.
- Trading 62% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review uniQure N.V..
Write a review
News about uniQure N.V.
News & sentiment via Polygon.io
